Janet L. Stein
Janet L. Stein has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Andre J. van Wijnen
Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655; and
4 shared publicationsGary S. Stein
Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655; and
4 shared publications- Amjad Javed
Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, Ala., USA
3 shared publications Jane B. Lian
Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655; and
2 shared publications- Jane B. Lian
Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, MA 01655; and
2 shared publications - Sayyed Kaleem Zaidi
American Association for Cancer Research , Philadelphia, Pennsylvania
2 shared publications
Latest Publications
- Open Access
- 7 November 2008
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (3) , 556-568
A Runx2 threshold for the cleidocranial dysplasia phenotype
Cleidocranial dysplasia (CCD) in humans is an autosomal-dominant skeletal disease that results from mutations in the bone-specific transcription factor RUNX2 (CBFA1/AML3). However, distinct RUNX2 mutations in CCD do not correlate with the severity of the disease. Here we generated a new mouse model with a hypomorphic Runx2 mutant allele (Runx2(neo7)), in which only part of the transcript is processed to full-length (wild-type) Runx2 mRNA. Homozygous Runx2(neo7/neo7) mice express a reduced level of wild-type Runx2 mRNA (55-70%) and protein. This mouse model allowed us to establish the minimal requirement of functional Runx2 for normal bone development. Runx2(neo7/neo7) mice have grossly normal skeletons with no abnormalities observed in the growth plate, but do exhibit developmental defects in calvaria and clavicles that persist through post-natal growth. Clavicle defects are caused by disrupted endochondral bone formation during embryogenesis. These hypomorphic mice have altered calvarial bone volume, as observed by histology and microCT imaging, and decreased expression of osteoblast marker genes. The bone phenotype of the heterozygous mice, which have 79-84% of wild-type Runx2 mRNA, is normal. These results show there is a critical gene dosage requirement of functional Runx2 for the formation of intramembranous bone tissues during embryogenesis. A decrease to 70% of wild-type Runx2 levels results in the CCD syndrome, whereas levels >79% produce a normal skeleton. Our findings suggest that the range of bone phenotypes in CCD patients is attributable to quantitative reduction in the functional activity of RUNX2.
- 7 November 2008
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (3) , 556-568
Open AccessA Runx2 threshold for the cleidocranial dysplasia phenotype
Cleidocranial dysplasia (CCD) in humans is an autosomal-dominant skeletal disease that results from mutations in the bone-specific transcription factor RUNX2 (CBFA1/AML3). However, distinct RUNX2 mutations in CCD do not correlate with the severity of the disease. Here we generated a new mouse model with a hypomorphic Runx2 mutant allele (Runx2(neo7)), in which only part of the transcript is processed to full-length (wild-type) Runx2 mRNA. Homozygous Runx2(neo7/neo7) mice express a reduced level of wild-type Runx2 mRNA (55-70%) and protein. This mouse model allowed us to establish the minimal requirement of functional Runx2 for normal bone development. Runx2(neo7/neo7) mice have grossly normal skeletons with no abnormalities observed in the growth plate, but do exhibit developmental defects in calvaria and clavicles that persist through post-natal growth. Clavicle defects are caused by disrupted endochondral bone formation during embryogenesis. These hypomorphic mice have altered calvarial bone volume, as observed by histology and microCT imaging, and decreased expression of osteoblast marker genes. The bone phenotype of the heterozygous mice, which have 79-84% of wild-type Runx2 mRNA, is normal. These results show there is a critical gene dosage requirement of functional Runx2 for the formation of intramembranous bone tissues during embryogenesis. A decrease to 70% of wild-type Runx2 levels results in the CCD syndrome, whereas levels >79% produce a normal skeleton. Our findings suggest that the range of bone phenotypes in CCD patients is attributable to quantitative reduction in the functional activity of RUNX2.
- 6 May 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (18) , 6632-6637
Phenotypic transcription factors epigenetically mediate cell growth control
Ribosomal RNA (rRNA) genes are down-regulated during osteogenesis, myogenesis, and adipogenesis, necessitating a mechanistic understanding of interrelationships between growth control and phenotype commitment. Here, we show that cell fate-determining factors [MyoD, myogenin (Mgn), Runx2, C/EBPβ] occupy rDNA loci and suppress rRNA expression during lineage progression, concomitant with decreased rRNA expression and reciprocal loss of occupancy by c-Myc, a proliferation-specific activator of rRNA transcription. We find interaction of phenotypic factors with the polymerase I activator upstream binding factor UBF-1 at interphase nucleoli, and this interaction is epigenetically retained on mitotic chromosomes at nucleolar organizing regions. Ectopic expression and RNA interference establish that MyoD, Mgn, Runx2, and C/EBPβ each functionally suppress rRNA genes and global protein synthesis. We conclude that epigenetic control of ribosomal biogenesis by lineage-specific differentiation factors is a general developmental mechanism for coordinate control of cell growth and phenotype.
- 6 May 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (18) , 6632-6637
Phenotypic transcription factors epigenetically mediate cell growth control
Ribosomal RNA (rRNA) genes are down-regulated during osteogenesis, myogenesis, and adipogenesis, necessitating a mechanistic understanding of interrelationships between growth control and phenotype commitment. Here, we show that cell fate-determining factors [MyoD, myogenin (Mgn), Runx2, C/EBPβ] occupy rDNA loci and suppress rRNA expression during lineage progression, concomitant with decreased rRNA expression and reciprocal loss of occupancy by c-Myc, a proliferation-specific activator of rRNA transcription. We find interaction of phenotypic factors with the polymerase I activator upstream binding factor UBF-1 at interphase nucleoli, and this interaction is epigenetically retained on mitotic chromosomes at nucleolar organizing regions. Ectopic expression and RNA interference establish that MyoD, Mgn, Runx2, and C/EBPβ each functionally suppress rRNA genes and global protein synthesis. We conclude that epigenetic control of ribosomal biogenesis by lineage-specific differentiation factors is a general developmental mechanism for coordinate control of cell growth and phenotype.
- 18 June 2007
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (1) , 136-148
The interactome of the histone gene regulatory factor HiNF‐P suggests novel cell cycle related roles in transcriptional control and RNA processing
HiNF‐P is a recently identified histone H4 subtype specific transcriptional regulator that associates with the conserved cell cycle control element in the proximal promoter regions of histone H4 genes. HiNF‐P interacts with the global histone gene regulator and direct cyclin E/CDK2 substrate p220NPAT to potently upregulate histone H4 gene transcription at the G1/S phase transition in response to cyclin E/CDK2 signaling. To gain insight into the function of HiNF‐P in a broader cellular context, we performed a yeast two‐hybrid screen to identify its novel interacting proteins. In this study, we detected 67 candidate HiNF‐P interacting proteins of varying cellular functions. We have identified multiple RNA associated proteins, including the splicing co‐factor SRm300. HiNF‐P and SRm300 interact in yeast two‐hybrid, co‐immunoprecipitation, and co‐immunofluorescence assays. Our screen also identified several gene regulators that associate with HiNF‐P including THAP7. HiNF‐P and THAP7 interact in mammalian cells and THAP7 abrogates HiNF‐P/p220 mediated activation of histone H4 gene transcription, consistent with its known role as a transcriptional repressor. Finally, we identified several proliferation related proteins including Ki‐67 and X transactivated protein 2 (XTP2) which may be functioning with HiNF‐P in cell cycle regulation. The HiNF‐P interactome indicates that HiNF‐P is a multifunctional gene regulator with a large functional network and roles beyond cell cycle‐dependent histone gene regulation. J. Cell. Biochem. 102: 136–148, 2007.
- 18 June 2007
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (1) , 136-148
The interactome of the histone gene regulatory factor HiNF‐P suggests novel cell cycle related roles in transcriptional control and RNA processing
HiNF‐P is a recently identified histone H4 subtype specific transcriptional regulator that associates with the conserved cell cycle control element in the proximal promoter regions of histone H4 genes. HiNF‐P interacts with the global histone gene regulator and direct cyclin E/CDK2 substrate p220NPAT to potently upregulate histone H4 gene transcription at the G1/S phase transition in response to cyclin E/CDK2 signaling. To gain insight into the function of HiNF‐P in a broader cellular context, we performed a yeast two‐hybrid screen to identify its novel interacting proteins. In this study, we detected 67 candidate HiNF‐P interacting proteins of varying cellular functions. We have identified multiple RNA associated proteins, including the splicing co‐factor SRm300. HiNF‐P and SRm300 interact in yeast two‐hybrid, co‐immunoprecipitation, and co‐immunofluorescence assays. Our screen also identified several gene regulators that associate with HiNF‐P including THAP7. HiNF‐P and THAP7 interact in mammalian cells and THAP7 abrogates HiNF‐P/p220 mediated activation of histone H4 gene transcription, consistent with its known role as a transcriptional repressor. Finally, we identified several proliferation related proteins including Ki‐67 and X transactivated protein 2 (XTP2) which may be functioning with HiNF‐P in cell cycle regulation. The HiNF‐P interactome indicates that HiNF‐P is a multifunctional gene regulator with a large functional network and roles beyond cell cycle‐dependent histone gene regulation. J. Cell. Biochem. 102: 136–148, 2007.
- 13 December 2006
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 25 (4) , 589-600
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone
The three mammalian Runt homology domain transcription factors (Runx1, Runx2, Runx3) support biological control by functioning as master regulatory genes for the differentiation of distinct tissues. Runx proteins also function as cell context-dependent tumor suppressors or oncogenes. Abnormalities in Runx mediated gene expression are linked to cell transformation and tumor progression. Runx2 is expressed in mesenchymal linage cells committed to the osteoblast phenotype and is essential for bone formation. This skeletal transcription factor is aberrantly expressed at high levels in breast and prostate tumors and cells that aggressively metastasize to the bone environment. In cancer cells, Runx2 activates expression of bone matrix and adhesion proteins, matrix metalloproteinases and angiogenic factors that have long been associated with metastasis. In addition, Runx2 mediates the responses of cells to signaling pathways hyperactive in tumors, including BMP/TGFβ and other growth factor signals. Runx2 forms co-regulatory complexes with Smads and other co-activator and co-repressor proteins that are organized in subnuclear domains to regulate gene transcription. These activities of Runx2 contribute to tumor growth in bone and the accompanying osteolytic disease, established by interfering with Runx2 functions in metastatic breast cancer cells. Inhibition of Runx2 in MDA-MB-231 cells transplanted to bone decreased tumorigenesis and prevented osteolysis. This review evaluates evidence that Runx2 regulates early metastatic events in breast and prostate cancers, tumor growth, and osteolytic bone disease. Consideration is given to the potential for inhibition of this transcription factor as a therapeutic strategy upstream of the regulatory events contributing to the complexity of metastasis to bone.
- 13 December 2006
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 25 (4) , 589-600
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone
The three mammalian Runt homology domain transcription factors (Runx1, Runx2, Runx3) support biological control by functioning as master regulatory genes for the differentiation of distinct tissues. Runx proteins also function as cell context-dependent tumor suppressors or oncogenes. Abnormalities in Runx mediated gene expression are linked to cell transformation and tumor progression. Runx2 is expressed in mesenchymal linage cells committed to the osteoblast phenotype and is essential for bone formation. This skeletal transcription factor is aberrantly expressed at high levels in breast and prostate tumors and cells that aggressively metastasize to the bone environment. In cancer cells, Runx2 activates expression of bone matrix and adhesion proteins, matrix metalloproteinases and angiogenic factors that have long been associated with metastasis. In addition, Runx2 mediates the responses of cells to signaling pathways hyperactive in tumors, including BMP/TGFβ and other growth factor signals. Runx2 forms co-regulatory complexes with Smads and other co-activator and co-repressor proteins that are organized in subnuclear domains to regulate gene transcription. These activities of Runx2 contribute to tumor growth in bone and the accompanying osteolytic disease, established by interfering with Runx2 functions in metastatic breast cancer cells. Inhibition of Runx2 in MDA-MB-231 cells transplanted to bone decreased tumorigenesis and prevented osteolysis. This review evaluates evidence that Runx2 regulates early metastatic events in breast and prostate cancers, tumor growth, and osteolytic bone disease. Consideration is given to the potential for inhibition of this transcription factor as a therapeutic strategy upstream of the regulatory events contributing to the complexity of metastasis to bone.
- 13 September 2006
- Published by Wiley in Journal of Cellular Physiology
- Vol. 209 (3) , 935-942
Alterations in intranuclear localization of Runx2 affect biological activity
The transcription factor Runx2 controls osteoblast proliferation and differentiation. Runx2 organizes and assembles gene‐regulatory complexes in nuclear microenvironments where target genes are activated or suppressed in a context‐dependent manner. Intranuclear localization of Runx2 is mediated by the nuclear matrix‐targeting signal (NMTS), an autonomous motif with a loop (L1)‐turn‐loop (L2) structure that forms predicted protein–protein interaction surfaces. Here we examined the functional consequences of introducing mutations in the L1 and L2 loops of the NMTS. These mutant proteins enter the nucleus, interact with the hetero‐dimeric partner Cbfβ, and bind to DNA in vitro and in vivo. In addition, these mutants retain interaction with the carboxy‐terminus interacting co‐regulatory proteins that include TLE, YAP, and Smads. However, two critical mutations in the L2 domain of the NMTS decrease association of Runx2 with the nuclear matrix. These subnuclear targeting defective (STD) mutants of Runx2 compromise target gene activation or repression. The biological significance of these findings is reflected by decreased osteogenic differentiation of mesenchymal progenitors, concomitant with major changes in gene expression profiles, upon expression of the STD Runx2 mutant. Our results demonstrate that fidelity of temporal and spatial localization of Runx2 within the nucleus is functionally linked with biological activity. J. Cell. Physiol. 209: 935–942, 2006.
- 13 September 2006
- Published by Wiley in Journal of Cellular Physiology
- Vol. 209 (3) , 935-942
Alterations in intranuclear localization of Runx2 affect biological activity
The transcription factor Runx2 controls osteoblast proliferation and differentiation. Runx2 organizes and assembles gene‐regulatory complexes in nuclear microenvironments where target genes are activated or suppressed in a context‐dependent manner. Intranuclear localization of Runx2 is mediated by the nuclear matrix‐targeting signal (NMTS), an autonomous motif with a loop (L1)‐turn‐loop (L2) structure that forms predicted protein–protein interaction surfaces. Here we examined the functional consequences of introducing mutations in the L1 and L2 loops of the NMTS. These mutant proteins enter the nucleus, interact with the hetero‐dimeric partner Cbfβ, and bind to DNA in vitro and in vivo. In addition, these mutants retain interaction with the carboxy‐terminus interacting co‐regulatory proteins that include TLE, YAP, and Smads. However, two critical mutations in the L2 domain of the NMTS decrease association of Runx2 with the nuclear matrix. These subnuclear targeting defective (STD) mutants of Runx2 compromise target gene activation or repression. The biological significance of these findings is reflected by decreased osteogenic differentiation of mesenchymal progenitors, concomitant with major changes in gene expression profiles, upon expression of the STD Runx2 mutant. Our results demonstrate that fidelity of temporal and spatial localization of Runx2 within the nucleus is functionally linked with biological activity. J. Cell. Physiol. 209: 935–942, 2006.
- Open Access
- 1 February 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (4) , 1460-1469
Maintenance of Open Chromatin and Selective Genomic Occupancy at the Cell Cycle-Regulated Histone H4 Promoter during Differentiation of HL-60 Promyelocytic Leukemia Cells
During the shutdown of proliferation and onset of differentiation of HL-60 promyelocytic leukemia cells, expression of the cell cycle-dependent histone genes is downregulated at the level of transcription. To address the mechanism by which this regulation occurs, we examined the chromatin structure of the histone H4/n (FO108, H4FN) gene locus. Micrococcal nuclease, DNase I, and restriction enzymes show similar cleavage sites and levels of sensitivity at the H4/n locus in both proliferating and differentiated HL-60 cells. In contrast, differentiation-related activation of the cyclin-dependent kinase inhibitor p21cip1/WAF1 gene is accompanied by increased nuclease hypersensitivity. Chromatin immunoprecipitation assays of the H4/n gene reveal that acetylated histones H3 and H4 are maintained at the same levels in proliferating and postproliferative cells. Thus, the chromatin of the H4/n locus remains in an open state even after transcription ceases. Using ligation-mediated PCR to visualize genomic DNase I footprints at single-nucleotide resolution, we find that protein occupancy at the site II cell cycle element is selectively diminished in differentiated cells while the site I element remains occupied. Decreased occupancy of site II is reflected by loss of the site II binding protein HiNF-P. We conclude that H4 gene transcription during differentiation is downregulated by modulating protein interaction at the site II cell cycle element and that retention of an open chromatin conformation may be associated with site I occupancy.
- 1 February 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (4) , 1460-1469
Open AccessMaintenance of Open Chromatin and Selective Genomic Occupancy at the Cell Cycle-Regulated Histone H4 Promoter during Differentiation of HL-60 Promyelocytic Leukemia Cells
During the shutdown of proliferation and onset of differentiation of HL-60 promyelocytic leukemia cells, expression of the cell cycle-dependent histone genes is downregulated at the level of transcription. To address the mechanism by which this regulation occurs, we examined the chromatin structure of the histone H4/n (FO108, H4FN) gene locus. Micrococcal nuclease, DNase I, and restriction enzymes show similar cleavage sites and levels of sensitivity at the H4/n locus in both proliferating and differentiated HL-60 cells. In contrast, differentiation-related activation of the cyclin-dependent kinase inhibitor p21cip1/WAF1 gene is accompanied by increased nuclease hypersensitivity. Chromatin immunoprecipitation assays of the H4/n gene reveal that acetylated histones H3 and H4 are maintained at the same levels in proliferating and postproliferative cells. Thus, the chromatin of the H4/n locus remains in an open state even after transcription ceases. Using ligation-mediated PCR to visualize genomic DNase I footprints at single-nucleotide resolution, we find that protein occupancy at the site II cell cycle element is selectively diminished in differentiated cells while the site I element remains occupied. Decreased occupancy of site II is reflected by loss of the site II binding protein HiNF-P. We conclude that H4 gene transcription during differentiation is downregulated by modulating protein interaction at the site II cell cycle element and that retention of an open chromatin conformation may be associated with site I occupancy.